Esphera SynBio | Synthetic Biology For The Treatment & Prevention Of Disease

Cells make exosomes. Esphera SynBio modifies cells such that they make modified exosomes.

These modified exosomes can be designed to have targeting moieties on their surface and a variety of protein or RNA payloads in their lumen.

Cells can be modified to do so in vitro (i.e. in a bioreactor) or in vivo (i.e. following delivery of our transgenes by any vector).

Watch our segment on advancements television with ted danson

click here – esphera at 13:49

our technology

Esphera designs transgenes encoding multimeric proteins that traffic into budding exosomes.

These multimeric proteins can include extravesicular targeting domains, luminal proteins (antigens, enzymes, adaptors etc) facilitating the packaging of various RNA species (siRNA, mRNA, saRNA).

This allows for the production of, for example, therapeutic exosomes in vivo.

Esphera’s lead application of this platform technology is the modification of tumour cells in vivo such that typically protumourigenic and immunosuppressive tumour-derived exosomes become immunostimulatory, antigen-bearing modifiers of the TME and bespoke, patient specific cancer vaccines.